S -1 or capecitabine combined with oxaliplatin in the treatment of advanced colorectal cancer
10.13699/j.cnki.1001-6821.2015.03.007
- VernacularTitle:替吉奥与卡培他滨联合奥沙利铂治疗晚期结直肠癌的临床研究
- Author:
Guo-Jun HUANG
1
;
Guang-Hong WANG
;
Chao GAO
;
Kai QIN
Author Information
1. 郫县人民医院肿瘤内科
- Keywords:
colorectal cancer;
S-1;
oxaliplatin;
capecitabine
- From:
The Chinese Journal of Clinical Pharmacology
2015;(3):181-183
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of S-1 or capecitabine combined with oxaliplatin regimens for advanced colorectal cancer.Methods Eighty patients with advanced colorectal cancer were divided into group A (40 cases) and group B (40 cases). Patients in group A were given S-1 80 mg· m-2 after meals, bid, and oxaliplatin 120 mg· d -1 through intravenous injection.Patients in group B were given capecitabine 1000 mg· m-2 after meals,bid, and oxalipla-tin 120 mg · d-1 through intravenous injection.The whole treatment lasted for 3 cycles in two groups, 14 days as a cycle.The data of clinical efficacy and adversed reactions were recorded and analyzed.Results The data of objective response rate ( ORR ) in group A and B were 35.0%and 32.5%respectively ( P<0.05 ).The one year survival rate were 52.5%and 50.0% in group A and B, respectively ( P>0.05 ).The incidence rate of adverse drug reactions such as nausea and vomiting in group A was much higher than that in group B ( P<0.05 ).No gradeⅣ adverse reaction was found in two groups.Conclusion There were no statistical difference in clinical efficacy of the two regimens in the treatment of advanced colorectal cancer , both with soft adverse reactions.
